Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19324396 | MARINE ORGANISM DERIVED SURFACTANT | September 2025 | February 2026 | Allow | 5 | 0 | 1 | No | No |
| 19252680 | LIQUID DISPENSING SYSTEM, COMPONENTS AND FEATURES THEREOF, AND METHODS OF USE THEREOF | June 2025 | March 2026 | Allow | 8 | 1 | 1 | No | No |
| 19206261 | PROCESS FOR CREATING A CANNABINOID PICO-EMULSION WITH ANTIBIOTIC PROPERTIES AND THE RESULTING PICO-EMULSION | May 2025 | February 2026 | Allow | 9 | 1 | 2 | No | No |
| 19183742 | ALBUMIN RICH PEA PROTEIN ISOLATE AND PROCESS FOR PRODUCTION THEREOF | April 2025 | September 2025 | Allow | 5 | 0 | 1 | No | No |
| 18773936 | OKRA-DERIVED ANTIVIRAL COMPOSITION AND USES THEREOF | July 2024 | May 2025 | Allow | 10 | 0 | 1 | No | No |
| 18746153 | MUNG BEAN HULL EXTRACT WITH ANTIVIRAL EFFECT AND EXTRACTION METHOD THEREOF | June 2024 | April 2025 | Allow | 10 | 0 | 1 | No | No |
| 18744608 | PROCESS FOR CREATING A CANNABINOID PICO-EMULSION WITH ANTIBIOTIC PROPERTIES AND THE RESULTING PICO-EMULSION | June 2024 | February 2026 | Allow | 20 | 0 | 1 | No | No |
| 18731591 | BIOCONTROL FORMULATION FOR CONTROLLING PLANT PATHOGENS | June 2024 | July 2025 | Allow | 14 | 2 | 1 | No | No |
| 18665693 | Chemical Processes And Apparatuses For Extracting Organic Compounds From Biomass With Volatile Organic Compound Removal | May 2024 | August 2024 | Allow | 3 | 0 | 1 | No | No |
| 18652734 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | May 2024 | March 2026 | Allow | 22 | 2 | 1 | No | No |
| 18650432 | CANNABIDIOL AND ACTIVE DELIVERY SYSTEMS | April 2024 | March 2025 | Allow | 10 | 0 | 0 | No | No |
| 18597236 | COMPOSITIONS COMPRISING CANNABIS AND MUSHROOM EXTRACTS, AND USES THEREOF | March 2024 | December 2024 | Allow | 9 | 0 | 0 | No | No |
| 18591599 | Composition Comprising Elderberry Extract as Effective Component for Preventing, Treating, or Alleviating Andropause Syndrome | February 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18591146 | ANTIMICROBIAL PEPTIDE STIMULATING SANITIZING COMPOSITION | February 2024 | October 2025 | Allow | 19 | 4 | 0 | No | No |
| 18421784 | ENCAPSULATED CANNABINOID COMESTIBLE NOBLE METAL COMPOSITIONS AND PRODUCTS, METHODS OF PREPARING SAME | February 2024 | March 2025 | Allow | 14 | 0 | 1 | No | No |
| 18436343 | TOPICAL SKIN COMPOSITIONS FOR TREATING ROSACEA AND SKIN REDNESS | February 2024 | December 2024 | Allow | 10 | 0 | 0 | No | No |
| 18433252 | CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USE | February 2024 | December 2024 | Allow | 10 | 0 | 2 | No | No |
| 18418553 | INDIVIDUAL DOSING OF CANNABIS AND TOBACCO FOR STANDARDIZATION AND CONTROL | January 2024 | August 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18417543 | TOPICAL SKIN FORMULATIONS | January 2024 | October 2024 | Allow | 9 | 0 | 0 | No | No |
| 18415101 | Mesenchymal Stem Cell Derived Exosomes And Methods | January 2024 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18401503 | PROTEIN BASED CANNABIS COMPOSITIONS | December 2023 | October 2024 | Allow | 10 | 0 | 0 | No | No |
| 18544077 | OIL EXTRACT OF CANNABIS AND METHOD FOR OBTAINING | December 2023 | May 2025 | Allow | 17 | 1 | 0 | No | No |
| 18537735 | SYNTHESIS OF A CARBON QUANTUM DOTS AND SILVER NANOPARTICLE COMPOSITION | December 2023 | May 2025 | Abandon | 18 | 2 | 1 | No | No |
| 18529935 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | December 2023 | July 2025 | Allow | 20 | 1 | 0 | No | No |
| 18521113 | COMPOSITIONS FOR SENSITIVE SKIN | November 2023 | October 2024 | Allow | 11 | 0 | 0 | No | No |
| 18520281 | COMPOSITION FOR SKIN-WHITENING OR PREVENTING OR IMPROVING SKIN WRINKLES COMPRISING GREEN TEA EXTRACT WHICH HAS MODIFIED AMOUNTS OF INGREDIENTS | November 2023 | September 2024 | Allow | 10 | 0 | 0 | No | No |
| 18513032 | MIXTURE FOR TREATMENT OF RESPIRATORY ILLNESSES | November 2023 | December 2024 | Abandon | 13 | 1 | 1 | No | No |
| 18511302 | A METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | November 2023 | March 2026 | Abandon | 27 | 2 | 0 | No | No |
| 18388981 | USES OF CURCUMINOID COMPOSITIONS | November 2023 | September 2024 | Allow | 10 | 0 | 0 | No | No |
| 18494658 | SEAWEED EXTRACTS, ISOLATED COMPOUNDS, AND METHODS OF TREATMENT | October 2023 | July 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18382338 | METHODS FOR PREPARATION OF PLECTRANTHUS AMBOINICUS EXTRACTS | October 2023 | May 2025 | Allow | 19 | 1 | 1 | No | No |
| 18490143 | WATER-BASED CANNABINOID AND OPIOID COMPOSITIONS | October 2023 | August 2024 | Allow | 10 | 0 | 0 | No | No |
| 18379585 | WATER SOLUBLE CANNABIS COMPOSITION | October 2023 | October 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18378020 | SYSTEM AND METHOD FOR AEROBIC RESPIRATORY TREATMENT | October 2023 | December 2025 | Allow | 26 | 0 | 0 | No | No |
| 18483161 | COMPOSITION AND FUNCTIONAL FOOD FOR PREVENTING MYOPIA | October 2023 | January 2026 | Abandon | 28 | 2 | 1 | No | No |
| 18375846 | Cannabinoid Compositions | October 2023 | August 2024 | Allow | 11 | 0 | 0 | No | No |
| 18368849 | APPARATUSES, METHODS, AND SYSTEMS FOR EXTRACTION, ISOLATION AND CONVERSION OF VARIOUS CANNABINOIDS, AND MODIFICATIONS OF WHOLE-PLANT HEMP EXTRACTS THEREWITH | September 2023 | March 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18244708 | METHOD AND COMPOSITION FOR PREVENTING AND TREATING COVID-19 AND LONG COVID | September 2023 | July 2024 | Allow | 10 | 0 | 0 | No | No |
| 18458727 | TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL | August 2023 | August 2024 | Allow | 11 | 0 | 0 | No | No |
| 18240004 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | August 2023 | May 2025 | Allow | 21 | 0 | 1 | No | No |
| 18232565 | DELIVERY OF ACTIVE INGREDIENTS FROM PLANT MATERIALS TO SKIN | August 2023 | August 2024 | Allow | 12 | 0 | 0 | No | No |
| 18276194 | PREPARATION METHOD FOR DECELLULARIZED MATRIX BIOMATERIAL | August 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18364692 | ARTIFICIAL TEARS AND THERAPEUTIC USES | August 2023 | February 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18354817 | COMPOSITIONS FOR PREVENTING AND TREATING VIRAL INFECTIONS | July 2023 | February 2026 | Abandon | 31 | 1 | 1 | No | No |
| 18351940 | Extraction and Purification of Cannabinoids | July 2023 | July 2024 | Allow | 12 | 0 | 0 | No | No |
| 18218279 | EXTRACTING VITAMINS B1 AND C FROM COMMIPHORA MYRRHA | July 2023 | November 2025 | Abandon | 28 | 2 | 1 | No | Yes |
| 18343563 | COMPOSITIONS COMPRISING CANNABIS AND MUSHROOM EXTRACTS, AND USES THEREOF | June 2023 | December 2023 | Allow | 6 | 0 | 1 | No | No |
| 18215797 | COMPOSITIONS AND METHODS FOR PREVENTING AND RECOVERY FROM DETRIMENTAL EFFECTS OF ALCOHOL CONSUMPTION | June 2023 | July 2024 | Allow | 13 | 0 | 0 | No | No |
| 18342018 | ORAL DISSOLVABLE FILM THAT INCLUDES PLANT EXTRACT | June 2023 | March 2025 | Allow | 21 | 0 | 1 | No | No |
| 18341980 | LONG TERM TREATMENT OF HAIR LOSS | June 2023 | September 2023 | Allow | 3 | 0 | 1 | No | No |
| 18213409 | FORTIFIED CBD OIL FOR TREATMENT OF PTSD | June 2023 | July 2024 | Allow | 12 | 0 | 0 | No | No |
| 18336575 | COMPOSITIONS AND METHODS FOR IMMUNE HEALTH | June 2023 | October 2023 | Allow | 4 | 0 | 1 | No | No |
| 18209267 | METHODS OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18204044 | Methods for Treating Neurological Disorders Using Nutrient Compositions | May 2023 | July 2024 | Allow | 14 | 0 | 0 | No | No |
| 18323860 | COMPOSITION AND METHOD FOR TREATING AUTISM | May 2023 | July 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18199797 | CANNABINOIDS COMPOSITIONS WITH POLYUNSATURATED FATTY ACID MONOGLYCERIDES, METHODS AND USES THEREOF | May 2023 | December 2024 | Allow | 19 | 0 | 1 | No | No |
| 18198312 | Use of Sustainable, Modified and Enhanced Aquaculture Limulus Amebocyte Lysate Protein and Hemolymph Compounds as a Biologic Broad Spectrum Antimicrobial Therapy. | May 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18251869 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FIBROSIS, COMPRISING ISOLATED MITOCHONDRIA | May 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18301603 | EMULSIONS AND DERIVATIVES FOR INFUSING HYDROPHOBIC ACTIVE AGENTS INTO AN EDIBLE PRODUCT | April 2023 | July 2024 | Allow | 15 | 0 | 0 | No | No |
| 18028327 | TOPICAL COMPOSITIONS CONTAINING MANUKA OIL AND PALMAROSA OIL FOR TREATING SKIN CONDITIONS | March 2023 | December 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18188162 | USE OF CANNABIDIOL IN TREATMENT OF PULMONARY HYPERTENSION | March 2023 | November 2023 | Allow | 7 | 0 | 0 | No | No |
| 18124460 | TREATMENT OF AUTISM WITH CANNABIDIOL | March 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18122556 | EXTRACTING VITAMINS B1 AND C FROM COMMIPHORA MYRRHA | March 2023 | November 2025 | Abandon | 32 | 3 | 1 | No | Yes |
| 18118316 | QUENCHERS THAT SLOW, DECREASE, OR INHIBIT THE FORMATION OF CHEMIEXCITATION-INDUCED CYCLOBUTANE PYRIMIDINE DIMERS | March 2023 | February 2025 | Abandon | 23 | 2 | 1 | No | No |
| 18172390 | BOYSENBERRY, APPLE, AND BLACKCURRANT COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREFOR | February 2023 | August 2024 | Allow | 17 | 1 | 1 | No | No |
| 18171983 | SLEEP DISORDER COMPOSITIONS AND TREATMENTS THEREOF | February 2023 | November 2024 | Allow | 20 | 2 | 0 | No | No |
| 18167765 | Solvent-Free THCA Extraction Process | February 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18163115 | NON-AQUEOUS GEL COMPOSITION | February 2023 | September 2025 | Allow | 31 | 0 | 0 | No | No |
| 18006765 | METHOD OF PREVENTING, REDUCING OR DELAYING FATTY LIVER DISEASE | January 2023 | December 2025 | Abandon | 35 | 0 | 1 | No | No |
| 18100758 | ANTIMICROBIAL COMPOSITIONS | January 2023 | March 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18100763 | TOPICAL SKIN COMPOSITIONS FOR TREATING ROSACEA AND SKIN REDNESS | January 2023 | November 2023 | Allow | 9 | 0 | 0 | No | No |
| 18099943 | INTRANASAL ADMINSTRATION OF CANNABIGEROL, CBDa, CBGa, & UNCARIA TOMENTOSA HYDROALCOHOLIC EXTRACT COMPOUNDS EMULSIFIED IN SALINE HOMOGENOUS SOLUTION FOR INTRANASAL ADMINISTRATION | January 2023 | December 2025 | Allow | 35 | 0 | 1 | No | No |
| 18097834 | TOPICAL SKIN FORMULATIONS | January 2023 | November 2023 | Allow | 10 | 0 | 0 | No | No |
| 18097959 | NANOEMULSION COMPOSITION OF LAVENDER OIL FOR FOOD PACKAGING | January 2023 | November 2024 | Allow | 22 | 0 | 1 | No | No |
| 18004945 | CANNABIS SATIVA EXTRACTS AND THEIR USES | January 2023 | April 2025 | Allow | 27 | 1 | 1 | No | No |
| 18095298 | DEEP EUTECTIC SOLVENT INCLUDING ONE OR MORE ACTIVE PHARMACEUTICAL INGREDIENTS DERIVED FROM MUSHROOMS | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18151117 | PROCESS FOR MAKING A WATER SOLUBLE, FULL SPECTRUM HEMP OIL | January 2023 | October 2025 | Abandon | 33 | 0 | 1 | No | No |
| 18085012 | COMPOSITIONS FOR SENSITIVE SKIN | December 2022 | August 2023 | Allow | 8 | 0 | 0 | No | No |
| 18067944 | OIL EXTRACT OF CANNABIS AND METHOD FOR OBTAINING | December 2022 | August 2023 | Allow | 8 | 0 | 0 | No | No |
| 18061328 | METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | December 2022 | August 2024 | Allow | 21 | 1 | 1 | No | No |
| 18072744 | INDIVIDUAL DOSING OF CANNABIS AND TOBACCO FOR STANDARDIZATION AND CONTROL | December 2022 | November 2023 | Allow | 11 | 0 | 1 | No | No |
| 18007660 | BONE GRAFT SUBSTITUTES | December 2022 | December 2025 | Allow | 36 | 1 | 1 | No | No |
| 17926161 | PLANT COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17990637 | CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USE | November 2022 | September 2023 | Allow | 20 | 0 | 2 | No | No |
| 17923721 | COMPOSITION FOR PROMOTING AND IMPROVING SLEEP AND BEVERAGE CONTAINING SAME, AND MANUFACTURING METHOD THEREOF | November 2022 | April 2025 | Allow | 30 | 0 | 1 | No | No |
| 17923749 | Uses and Formulations of Cannabinoids | November 2022 | October 2025 | Abandon | 35 | 0 | 1 | No | No |
| 18052545 | COMPOSITIONS AND METHODS FOR PREVENTING AND RECOVERY FROM DETRIMENTAL EFFECTS OF ALCOHOL CONSUMPTION | November 2022 | June 2023 | Allow | 7 | 0 | 0 | No | No |
| 17977835 | COMPOSITIONS AND METHODS OF CONTROLLING PESTS | October 2022 | December 2025 | Allow | 38 | 0 | 2 | No | No |
| 17921142 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF IN TREATING MUSCLE ATROPHY | October 2022 | May 2025 | Allow | 31 | 0 | 1 | No | No |
| 18048954 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | October 2022 | July 2023 | Allow | 9 | 0 | 0 | No | No |
| 17970395 | TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL | October 2022 | May 2025 | Allow | 30 | 0 | 1 | No | No |
| 17918410 | COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS | October 2022 | November 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17961940 | LABISIA PUMILA EXTRACT COMPOSITION AND ITS PHARMACEUTICAL FORMULATION | October 2022 | July 2025 | Allow | 33 | 0 | 1 | No | No |
| 17960379 | METHODS FOR REMOVING CONTAMINANTS FROM PLANT-DERIVED PHARMACEUTICALS | October 2022 | October 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17959284 | MEDICATION SYSTEM | October 2022 | July 2024 | Allow | 21 | 0 | 0 | No | No |
| 17937463 | WATER-BASED CANNABINOID AND OPIOID COMPOSITIONS | October 2022 | July 2023 | Allow | 9 | 0 | 0 | No | No |
| 17936506 | Soft Gummy | September 2022 | July 2025 | Allow | 33 | 0 | 0 | No | No |
| 17956814 | METHOD TO TREAT VITILIGO | September 2022 | February 2024 | Abandon | 17 | 0 | 1 | No | No |
| 17915233 | MEANS AND METHODS FOR ENHANCING CANNABINOIDS EFFICACY | September 2022 | October 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17906989 | PLATELET LYSATE FOAM FOR CELL CULTURE, CELL THERAPY AND TISSULAR REGENERATION AND METHOD FOR OBATINING SAME | September 2022 | October 2025 | Abandon | 37 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MELLER, MICHAEL V.
With a 54.2% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 37.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner MELLER, MICHAEL V works in Art Unit 1655 and has examined 1,835 patent applications in our dataset. With an allowance rate of 66.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.
Examiner MELLER, MICHAEL V's allowance rate of 66.9% places them in the 28% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MELLER, MICHAEL V receive 1.11 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MELLER, MICHAEL V is 25 months. This places the examiner in the 78% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a -2.3% benefit to allowance rate for applications examined by MELLER, MICHAEL V. This interview benefit is in the 8% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 20.5% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 11.6% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 83.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 76.7% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 44.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 59.8% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 9.3% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.